Supplement

Unique Features of Genome Sequencing for Rare Disease Diagnosis

Contents: Methods…………………………………………………………………………………………...**2 Sequencing**………………………………………………………………………………..**2 Analysis**……….…………………………………………………………………………..**3 Variant classification**………………………………...…………………………………..**5 References**………………………………...…………………………...…...……………………..**5 Table S1 Standard searches used by the Broad team for ES/GS analysis**…………..…...…...**9 Figure S1 Classification of variants**..……………………….………………………..…...…...**10 Table S2. Diagnoses**..…………………………………………………...……………..…...…...**11 Table S3. Candidates**..…………………………………………….…………………..…...…...**12 Table S4. Diagnostic yield by imputed ancestry**..…………………………………...…...…...**15**

Sequencing Methods

Genome sequencing (GS) was performed by the Genomics Platform at the Broad Institute of MIT and Harvard. PCR-free preparation of sample DNA $(350 \text{ ng input at} > 2 \text{ ng/ul})$ is accomplished using Illumina HiSeq X Ten v2 chemistry. Libraries are sequenced to a mean target coverage of 30x. GS data was processed through a pipeline based on Picard, using base quality score recalibration and local realignment at known indels. The BWA aligner was used for mapping reads to the human genome build 38 (GRCh38). Single nucleotide variants and insertions/deletions (indels) were jointly called across all samples using Genome Analysis Toolkit (GATK) HaplotypeCaller package version 4.0. Default filters were applied to SNV and indel calls using the GATK Variant Quality Score Recalibration (VQSR) approach. Annotation was performed using Variant Effect Predictor (VEP). GATK-SV¹ was used to detect structural variants (SVs), which were annotated with the GATK SVAnnotate tool. Mitochondrial DNA (mtDNA) single nucleotide and small indel variants were called from GS data using the gnomAD-mitochondria pipeline² and large mtDNA deletions were called by MitoSAlt³. ExpansionHunter v5 was used to genotype known disease-associated tandem repeat expansions (TREs).4 Lastly, the variant call set was uploaded to *seqr* for collaborative analysis between the CMG and investigator or for analysis by the RGP team.⁵

ES was performed prior to GS for many of these cases through a variety of clinical diagnostic laboratories or by the Genomics Platform at the Broad Institute. For these cases, libraries from DNA samples (>250 ng of DNA, at >2 ng/ul) were created with an Illumina Nextera exome capture (38 Mb target) and sequenced (150 bp paired reads) to cover >80% of targets at 20x and a mean target coverage of 80x until January 2019 and thereafter using a Twist exome capture (~38 Mb target) and sequenced (150 bp reads) to cover > 90% of targets at 20x and a mean target coverage of 80x. Sample identity quality assurance checks were performed on each sample. The ES data was de-multiplexed and each sample's sequence data were aggregated into a single Picard BAM file. ES data was subsequently processed similar to GS data as previously described.

Analysis

The Broad CMG analysis team has developed four standard searches that are applied for each family (Table S1). We prioritize variants for further study that have high pathogenicity scores using common *in silico* predictors (e.g. REVEL⁶, CADD⁷, SIFT⁸, PolyPhen-2⁹,

MutationTaster¹⁰, MPC¹¹), occur at highly conserved residues as determined by manual review on the UCSC genome browser and evaluating the Genomic Evolutionary Rate Profiling (GERP) score¹². We visually inspect the read data using the Integrated Genomics Viewer (IGV) for our candidate variants to ensure they are not sequencing artifacts. Top candidate variants are typically confirmed by an orthogonal method such as Sanger sequencing.

To detect SVs, we initially utilized multiple SV-calling tools including Manta¹³, DELLY¹⁴, and Smoove (https://github.com/brentp/smoove), and more recently applied GATK-SV: an ensemble SV detection tool that discovers, genotypes, and resolves the diverse classes of SVs that can be captured from GS data, including balanced and unbalanced CNVs, inversions, insertions, translocations, and a spectrum of complex SVs. Briefly, GATK-SV maximizes sensitivity by harmonizing five algorithms, then adjudicating and re-genotyping SVs from raw read evidence¹. GATK-SV considers all SV evidence available from GS, including discordant paired-end (PE) or split reads (SR) crossing a breakpoint, and normalized read-depth (RD) or B-allele frequencies. Each CRAM file is processed with five algorithms, which currently include two PE/SR algorithms (Manta¹³, Wham¹⁵), two RD algorithms (cnMOPS¹⁶ and GATK-gCNV¹⁷), and a

mobile element algorithm, MELT¹⁸. GATK-SV is publicly available on GitHub (https://github.com/broadinstitute/gatk-sv). For CNV analysis, we also apply germline Copy Number Variant caller (gCNV), a coverage-based CNV detection method that normalizes coverage across the exome by adjusting for systematic bias and uses a probabilistic framework to infer copy number from the normalized coverage. We manually evaluate the CNV data, filtering out low-quality calls and inherited variants (based on family history) and focus our analysis on CNVs overlapping protein-coding genes. For cases with a strong phenotype pointing to a particular gene or genes as the likely candidate, we may also manually search for SVs by visually-inspecting the reads across the gene in question (using the Integrated Genomics Viewer 19).

To evaluate for tandem repeat expansions (TREs), we run ExpansionHunter $v5^{20}$ on GS samples to genotype 60 known disease-associated repeat loci. The locus specifications we use are publicly available on github (https://github.com/broadinstitute/str-analysis) and represent the same list of loci for which population frequencies are available in the gnomAD browser (https://gnomad.broadinstitute.org/short-tandem-repeats?dataset=gnomad_r3). We also run $REViewer²¹$ to generate read visualizations. Then, to identify candidate pathogenic expansions, we evaluate individuals with the most-expanded genotypes for each locus, comparing them to the pathogenic threshold and population frequencies for this locus in gnomAD. We also evaluate genotype qualities based on reviewing read visualizations.

To evaluate mtDNA SNVs and indels, we run the mitochondria mode of Mutect2 followed by the gnomAD-mitochondria pipeline². Then, to identify candidate variants, we search for "confirmed" variants listed in MITOMAP22 and P/LP variants listed in ClinVar. We finally review all mtDNA variants of uncertain significance (VUS) reported in ClinVar and/or with

"reported" status in MITOMAP, in addition to unreported variants with pathogenic *in silico* prediction based on mtDNA-specifications of the ACMG/AMP guidelines (APOGEE > 0.5 for missense variants; MitoTIP > 12.66 plus $HmtVar > 0.35$ for tRNA variants), that are absent at high heteroplasmy level (>80%) or homoplasmy (> 95%) in reference databases (gnomAD v3 and HelixMTdb).

Variant classification

In order to systematically assess the pathogenicity of the structural variants that we identified, the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen) standards for classification and reporting of constitutional copy-number variants were applied²³. Variants in novel gene-disease relationships are classified as VUS until the gene-disease relationship has at least moderate evidence supporting it. CNV associated with disorders that follow an autosomal recessive or X-linked mode of inheritance are not addressed in these standards and required additional consideration; the classification criteria were modified to optimally capture evidence for pathogenicity for the range of variants that we identified. Relative proportions of VUS to pathogenic/likely pathogenic variants are presented in Figure S1.

References

- 1. Collins RL, Brand H, Karczewski KJ, et al. A structural variation reference for medical and population genetics. Nature 2020;581(7809):444-451.
- 2. Laricchia KM, Lake NJ, Watts NA, et al. Mitochondrial DNA variation across 56,434 individuals in gnomAD. Genome Res 2022;32(3):569-582.
- 3. Basu S, Xie X, Uhler JP, et al. Accurate mapping of mitochondrial DNA deletions and duplications using deep sequencing. PLoS Genet 2020;16(12):e1009242.
- 4. Dolzhenko E, Deshpande V, Schlesinger F, et al. ExpansionHunter: a sequence-graphbased tool to analyze variation in short tandem repeat regions. Bioinformatics 2019;35(22):4754-4756.
- 5. Pais LS, Snow H, Weisburd B, et al. seqr: A web-based analysis and collaboration tool for rare disease genomics. Hum Mutat 2022;43(6):698-707.
- 6. Ioannidis NM, Rothstein JH, Pejaver V, et al. REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. Am J Hum Genet 2016;99(4):877-885.
- 7. Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet 2014;46(3):310-5.
- 8. Sim NL, Kumar P, Hu J, Henikoff S, Schneider G, Ng PC. SIFT web server: predicting effects of amino acid substitutions on proteins. Nucleic Acid Res 2012;40:452.
- 9. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods 2010;7(4):248-9.
- 10. Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation prediction for the deep-sequencing age. Nature methods 2014;11(4):361-362.
- 11. Kaitlin E. Samocha, Jack A. Kosmicki, Konrad J. Karczewski, Anne H. O'Donnell-Luria, Emma Pierce-Hoffman, Daniel G. MacArthur, Benjamin M. Neale, Mark J. Daly. bioRxiv 148353; doi: https://doi.org/10.1101/148353.
- 12. Huber CD, Kim BY, Lohmueller KE. Population genetic models of GERP scores suggest pervasive turnover of constrained sites across mammalian evolution. PLoS Genet 2020;16(5):e1008827.
- 13. Chen X, Schulz-Trieglaff O, Shaw R, et al. Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications. Bioinformatics 2016;32(8):1220-2.
- 14. Rausch T, Zichner T, Schlattl A, Stutz AM, Benes V, Korbel JO. DELLY: structural variant discovery by integrated paired-end and split-read analysis. Bioinformatics 2012;28(18):i333-i339. .
- 15. Kronenberg ZN, Osborne EJ, Cone KR, et al. Wham: Identifying Structural Variants of Biological Consequence. PLoS Comput Biol 2015;11(12):e1004572.
- 16. Klambauer G, Schwarzbauer K, Mayr A, et al. cn.MOPS: mixture of Poissons for discovering copy number variations in next-generation sequencing data with a low false discovery rate. Nucleic Acids Res 2012;40(9):e69.
- 17. Fu JM, Satterstrom FK, Peng M, et al. Rare coding variation provides insight into the genetic architecture and phenotypic context of autism. Nat Genet 2022;54(9):1320-1331.
- 18. Gardner EJ, Lam VK, Harris DN, et al. The Mobile Element Locator Tool (MELT): population-scale mobile element discovery and biology. Genome Res 2017;27(11):1916- 1929.
- 19. Thorvaldsdóttir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): highperformance genomics data visualization and exploration. Brief Bioinform 2013;14(2):178-92.
- 20. Dolzhenko E, van Vugt J, Shaw RJ, et al. Detection of long repeat expansions from PCRfree whole-genome sequence data. Genome Res 2017;27(11):1895-1903.
- 21. Dolzhenko E, Weisburd B, Ibanez K, et al. REViewer: haplotype-resolved visualization of read alignments in and around tandem repeats. Genome Med 2022;14(1):84.
- 22. Kogelnik AM, Lott MT, Brown MD, Navathe SB, Wallace DC. MITOMAP: a human mitochondrial genome database--1998 update. Nucleic Acids Res 1998;26(1):112-5.
- 23. Riggs ER, Andersen EF, Cherry AM, et al. Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). Genet Med 2020;22(2):245-257.
- 24. Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 2020;581(7809):434-443.
- 25. Jaganathan K, Kyriazopoulou Panagiotopoulou S, McRae JF, et al. Predicting Splicing from Primary Sequence with Deep Learning. Cell 2019;176(3):535-548.e24.

Search	Variant annotations	Variant frequency (Broad callset, gnom AD^{24} , gnomAD $SV1$)	Variant call quality	Annotation overrides (SpliceAI score 25)
Dominant/de novo restrictive	Coding variants, essential and extended splice site, LOF SVs	0.001 gnomAD 0.01 callset	Pass VQSR GQ 40 AB 20	ClinVar LP/P SpliceAI >0.2
Recessive restrictive	Coding variants, essential and extended splice site, LOF SVs	0.01 gnom AD 0.03 callset	Pass VQSR GQ 40 AB 20	ClinVar LP/P SpliceAI >0.2
Dominant/de novo permissive	Coding variants, synonymous, splice, 5/3'UTR, Non-coding exons, TFBS, regulatory region, LOF/intronic/UTR/promoter SVs	0.001 gnom AD 0.01 callset	GQ 40 AB 10	ClinVar LP/P/VUS Splice $AI > 0.1$
Recessive permissive	Coding variants, synonymous, splice, 5/3'UTR, Non-coding exons, TFBS, regulatory region, LOF/intronic/UTR/promoter SVs	0.01 gnom AD 0.03 callset	GQ 40 AB 10	ClinVar LP/P/VUS SpliceAI > 0.1

Table S1: Standard searches used by the Broad team for ES/GS analysis

Legend: LOF: Loss of function; VQSR: Variant Quality Score Recalibration; GQ: Genotype quality; AB: allele balance; LP/P: Likely pathogenic/pathogenic; UTR: Untranslated region; TFBS: transcription factor binding site; VUS: Variant of uncertain significance

Figure S1. Classification of variants. Pathogenicity of 284 variants in 218 families solved via GS, classified as per the ACMG/AMP/ClinGen standards.

Table S2. Diagnoses See separate spreadsheet

ID	Gene	
UWA LAI963	ABCD3	
HK115	ACSL5	
SCO PED096	ADGRE3	
BON B17-59	AFAPILI	
SOU FAM00008	AGMAT	
HK103	ANO1	
HK081	ANO ₂	
RGP 696	ARFGEF3	
CHU 05	ARHGAP6	
RGP 245	BAZIB	
RGP 12	BLOCISI	
RGP 655	BOD1	
CHU 23	C10orf71	
RGP 572	CACNA2D3	
RGP 658	CAMK1D	
RGP 284	CAMK4	
HK060	CBX8	
HK017	CDK11B	
RGP 735	CDK16	
IK	CDK5RAP3	
RGP 1374	CEP192	
BEG 0761	CFAP46	
RGP 868	CFAP54	
CMG Laing Ravencroft WGS	COL5A3	
RGP 1333	DIPK2B	
RGP 45	DNAH17	
RGP 1149	EBF2	
49	<i>ELK1</i>	
UWA LAI1646	EP400	
RGP 726	EPHA6	
RGP 54	ERICH3	
RGP 1268	<i>ETV1</i>	
827	<i>FAM193A</i>	
RGP 1180	FBXO42	
RGP 375	FGF7	
HK085	FLYWCH1	
RGP 1150	FRG2	

Table S3. Candidates. Candidate novel disease genes identified in this cohort.

Ancestry Category	Total	Diagnosed
	(N, % of cohort)	(N, % of subgroup)
African/African	$22(3.0\%)$	5(22%)
American		
Ashkenazi Jewish	$33(4.4\%)$	20(61%)
East Asian	$12(1.6\%)$	2(17%)
European	570 (76.6%)	170(43%)
Latino/Admixed	$27(3.6\%)$	4(15%)
American		
Middle Eastern	$2(0.3\%)$	$1(50\%)$
South Asian	$13(1.7\%)$	4(31%)
Multiple/Unknown	65 (8.7%)	19(29%)

Table S4. Diagnostic yield by imputed ancestry